Clinical Trial Search

Primary: Number of Participants With Cessation Success at Week 10 After Target Quit Date — 12; 7 Participants with cessation success

Primary: Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks — 3; 5 Participants

Primary: Number and Percentage of Subjects With Successful Bowel Cleansing — 25; 22; 19 Participants — p=0.003

Primary: Changes in Tumor Tissue Microvessel Density [MVD] From Baseline — 0.005 Percent area fraction

Primary: Peak Plasma Concentration (Cmax) of Aripiprazole in Cohort 1 — 18.8; 16.9 ng/mL

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 4; 3; 4; 3 Participants

Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001

Primary: Number of Participants With Premature Ovarian Insufficiency — 10; 38 Participants

Primary: Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12 — -1.12; -2.56; -1.52; -1.32 units on a scale — p=<0.001

Primary: Percentage of Participants Who Developed Factor VIII (FVIII) Inhibitors — 0 percentage of participants

Primary: Pregnancy Rate — 2.1 percentage of participants

Primary: Number of Participants With Complete Remission (CR) — 68 Participants

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059

Primary: Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour) — 22.77; 22.41; 5.00; 3.79 mmHg

Primary: Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months — 23; 19; 18; 29 Participants